In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
William M McFaddenCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-6911-2172 Karen A KirbyCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-2468-4796 Zachary C LorsonCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0009-0002-1404-9086 Lei WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Carolyn M HighlandDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.ORCID 0000-0003-4029-0113 Sophie R HarveyCampus Chemical Instrumentation Center Mass Spectrometry and Proteomics Facility, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-0763-8173 Savannah BrancatoCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-9267-500X Andres Emanuelli CastanerCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0009-0005-1275-9684 Haijuan DuCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Vicki H WysockiSchool of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0003-0495-2538 Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-1326-5986 Robert A DickCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-3693-2531 Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-5840-154X Funding
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MStructural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Andrew Laurence Routh · 2022 to 2026
$36.7MStructural studies of HIV Capsid with host factors and Capsid-targeting antiviralsR01AI120860 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI Stefan G Sarafianos, Zhengqiang Wang · 2015 to 2026
$6.0MNative Mass Spectrometry Guided Structural Biology CenterRM1GM149374 · NIGMS · OHIO STATE UNIVERSITY · PI Vicki H. Wysocki · 2023 to 2026
$5.0MTraining Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8MNovel HIV capsid-targeting antivirals maintain activity against lenacapavir-resistant virusesR21AI189247 · NIAID · EMORY UNIVERSITY · PI Karen A Kirby · 2025 to 2026
$457kStructural and Biochemical Effects of Capsid-targeting Molecules on HIV-1 Capsid AssemblyF31AI174951 · NIAID · EMORY UNIVERSITY · PI WILLIAM MICHAEL MCFADDEN · 2023 to 2026
$196kNIAID NIH HHS F31 AI174951NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI120860NIAID NIH HHS R21 AI189247NIAID NIH HHS U54 AI170855NIGMS NIH HHS RM1 GM149374NIGMS NIH HHS T32 GM135060
6 · The paper itselfAbstract
The HIV-1 capsid is an essential viral component, targeted by the long-acting antiretroviral Lenacapavir (LEN). LEN binds to the HIV-1 capsid protein (CA) at the phenylalanine-glycine (FG) binding pocket (FGBP), a site for multiple host-factor and antiviral interactions in CA hexamers (CA
Indexed as
CapsidElectron MicroscopyHIV-1LenacapavirStructural biology
Identifiers
PMID41889801
PMCPMC13015717
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390